ORF8 和 ORF3b 抗体是 SARS-CoV-2 早期和晚期感染的准确血清学标志物。

ORF8 and ORF3b antibodies are accurate serological markers of early and late SARS-CoV-2 infection.

机构信息

HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.

Faculté de Médecine Université Paris Descartes, Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Universitaire Paris Centre, Centre Hospitalier Universitaire Cochin, Service d'Immunologie Biologique, Paris, France.

出版信息

Nat Immunol. 2020 Oct;21(10):1293-1301. doi: 10.1038/s41590-020-0773-7. Epub 2020 Aug 17.

DOI:10.1038/s41590-020-0773-7

PMID:32807944

Abstract

The SARS-CoV-2 virus emerged in December 2019 and has caused a worldwide pandemic due to the lack of any pre-existing immunity. Accurate serology testing is urgently needed to help diagnose infection, determine past exposure of populations and assess the response to a future vaccine. The landscape of antibody responses to SARS-CoV-2 is unknown. In this study, we utilized the luciferase immunoprecipitation system to assess the antibody responses to 15 different SARS-CoV-2 antigens in patients with COVID-19. We identified new targets of the immune response to SARS-CoV-2 and show that nucleocapsid, open reading frame (ORF)8 and ORF3b elicit the strongest specific antibody responses. ORF8 and ORF3b antibodies, taken together as a cluster of points, identified 96.5% of COVID-19 samples at early and late time points of disease with 99.5% specificity. Our findings could be used to develop second-generation diagnostic tests to improve serological assays for COVID-19 and are important in understanding pathogenicity.

摘要

严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）于 2019 年 12 月出现，由于缺乏任何预先存在的免疫力，已导致全球大流行。迫切需要准确的血清学检测来帮助诊断感染、确定人群的既往暴露情况，并评估对未来疫苗的反应。目前尚不清楚针对 SARS-CoV-2 的抗体反应情况。在这项研究中，我们利用荧光素酶免疫沉淀系统评估了 15 种不同 SARS-CoV-2 抗原在 COVID-19 患者中的抗体反应。我们确定了针对 SARS-CoV-2 的免疫反应的新靶点，并表明核衣壳、开放阅读框（ORF）8 和 ORF3b 引发了最强的特异性抗体反应。ORF8 和 ORF3b 抗体作为一个点簇，在疾病的早期和晚期阶段可识别 96.5%的 COVID-19 样本，特异性为 99.5%。我们的发现可用于开发第二代诊断测试，以改进针对 COVID-19 的血清学检测，这对于了解致病性很重要。